mayzent 0.25 mg
novartis israel ltd - siponimod as fumaric acid - film coated tablets - siponimod as fumaric acid 0.25 mg - siponimod - mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include relapsing-remitting disease, and active secondary progressive disease, in adults.
mayzent 2 mg
novartis israel ltd - siponimod as fumaric acid - film coated tablets - siponimod as fumaric acid 2 mg - siponimod - mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include relapsing-remitting disease, and active secondary progressive disease, in adults.
mayzent
novartis europharm limited - siponimod fumaric acid - multiple sclerosis, relapsing-remitting - selective immunosuppressants - mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (spms) with active disease evidenced by relapses or imaging features of inflammatory activity.
kiendra 0.25mg film-coated tablet
novartis corporation (malaysia) sdn. bhd. - siponimod fumaric acid -
kiendra 2mg film-coated tablet
novartis corporation (malaysia) sdn. bhd. - siponimod fumaric acid -
mayzent film-coated tablet 0.25mg
novartis (singapore) pte ltd - siponimod fumaric acid equiv siponimod - tablet, film coated - siponimod fumaric acid equiv siponimod 0.25mg
mayzent film-coated tablet 2mg
novartis (singapore) pte ltd - siponimod fumaric acid equiv siponimod - tablet, film coated - siponimod fumaric acid equiv siponimod 2mg
mayzent tablet
novartis pharmaceuticals canada inc - siponimod - tablet - 0.25mg - siponimod 0.25mg - immunomodulatory agents
mayzent tablet
novartis pharmaceuticals canada inc - siponimod - tablet - 2mg - siponimod 2mg - immunomodulatory agents
mayzent 2 mg
شركة مستودع الأدوية الأردني - the jordan drugstore co - siponimod fumaric acid 2 mg - 2 mg